1	As	as	IN	_	7	mark	_
2	an	an	DT	_	6	det	_
3	eagerly	eagerly	RB	_	5	hmod	_
4	-	-	HYPH	_	5	hyph	_
5	anticipated	anticipate	VBN	_	6	amod	_
6	debate	debate	NN	_	7	nsubj	7:A1=PPT
7	kicks	kick	VBZ	p2=NNS|pb=kick.04	28	advcl	28:AM-ADV
8	off	off	RP	_	7	prt	7:C-V
9	at	at	IN	_	7	prep	7:AM-LOC
10	the	the	DT	_	14	det	_
11	American	american	NNP	p2=JJ	13	nn	_
12	Thoracic	thoracic	NNP	_	13	nn	_
13	Society	society	NNP	_	14	nn	_
14	conference	conference	NN	_	9	pobj	_
15	in	in	IN	_	14	prep	_
16	San	san	NNP	_	17	nn	_
17	Diego	diego	NNP	_	15	pobj	_
18	on	on	IN	_	14	prep	_
19	drugs	drug	NNS	_	18	pobj	_
20	for	for	IN	_	14	prep	_
21	idiopathic	idiopathic	JJ	p2=NN	23	amod	_
22	pulmonary	pulmonary	JJ	_	23	amod	_
23	fibrosis	fibrosis	NN	_	20	pobj	_
24	,	,	,	_	28	punct	_
25	Boehringer	boehringer	NNP	_	26	nn	_
26	Ingelheim	ingelheim	NNP	_	28	nsubj	28:A0=PAG
27	has	have	VBZ	_	28	aux	_
28	posted	post	VBN	pb=post.01	0	root	_
29	promising	promising	JJ	p2=VBG	33	amod	_
30	late	late	JJ	_	32	hmod	_
31	-	-	HYPH	_	32	hyph	_
32	stage	stage	NN	_	33	nn	_
33	data	datum	NNS	_	28	dobj	28:A1=PPT
34	on	on	IN	_	28	prep	_
35	its	its	PRP$	_	36	poss	_
36	offering	offering	NN	_	34	pobj	_
37	,	,	,	_	36	punct	_
38	nintedanib	nintedanib	NNP	p2=UH	36	appos	_
39	.	.	.	_	28	punct	_

1	The	the	DT	_	2	det	_
2	company	company	NN	_	4	nsubj	4:A0=PAG
3	has	have	VBZ	_	4	aux	_
4	published	publish	VBN	pb=publish.01	0	root	_
5	data	datum	NNS	p2=NN	4	dobj	4:A1=PRD
6	from	from	IN	_	4	prep	4:AM-LOC
7	the	the	DT	_	12	det	_
8	two	#crd#	CD	_	12	num	_
9	Phase	phase	NNP	p2=NN	10	nn	_
10	III	iii	NNP	p2=CD	11	nn	_
11	INPULSIS	inpulsis	NNP	p2=NN	12	nn	_
12	trials	trial	NNS	_	6	pobj	13:A2=PPT
13	involving	involve	VBG	pb=involve.01	12	partmod	_
14	1,066	0	CD	_	15	num	_
15	patients	patient	NNS	_	13	dobj	17:A0=CAU;13:A1=PPT
16	,	,	,	_	15	punct	_
17	showing	show	VBG	pb=show.01	15	partmod	_
18	that	that	IN	p2=DT	20	complm	_
19	nintedanib	nintedanib	NNP	p2=CD	20	nsubj	20:A0=PAG
20	met	meet	VBD	pb=meet.02	17	ccomp	17:A1=PPT
21	its	its	PRP$	_	23	poss	_
22	primary	primary	JJ	_	23	amod	_
23	endpoint	endpoint	NN	_	20	dobj	20:A1=COM
24	of	of	IN	_	23	prep	_
25	slowing	slow	VBG	pb=slow.01	24	pcomp	_
26	disease	disease	NN	p2=JJ	27	nn	_
27	progression	progression	NN	_	25	dobj	25:A1=PPT
28	.	.	.	_	4	punct	_

1	Specifically	specifically	RB	_	6	advmod	6:AM-DIS
2	,	,	,	_	6	punct	_
3	the	the	DT	_	4	det	_
4	drug	drug	NN	_	6	nsubj	6:A0
5	significantly	significantly	RB	_	6	advmod	6:A2=EXT
6	reduced	reduce	VBD	p2=VBN|pb=reduce.01	0	root	_
7	the	the	DT	_	9	det	_
8	annual	annual	JJ	_	9	amod	_
9	decline	decline	NN	_	6	dobj	6:A1=PPT
10	in	in	IN	_	9	prep	_
11	forced	force	VBN	p2=JJ|pb=force.02	13	amod	_
12	vital	vital	JJ	p2=NN	13	amod	_
13	capacity	capacity	NN	_	10	pobj	11:A1=PPT
14	(	(	-LRB-	_	15	punct	_
15	FVC	fvc	NNP	p2=NN	13	appos	_
16	)	)	-RRB-	_	15	punct	_
17	by	by	IN	_	6	prep	_
18	some	some	DT	_	19	quantmod	_
19	50	0	CD	_	20	num	_
20	%	%	NN	_	17	pobj	_
21	compared	compare	VBN	_	6	prep	6:AM-ADV
22	to	to	IN	_	21	prep	_
23	patients	patient	NNS	_	22	pobj	24:A0
24	taking	take	VBG	pb=take.01	23	partmod	_
25	placebo	placebo	NN	_	24	dobj	24:A1=PPT
26	over	over	IN	_	24	prep	24:AM-TMP
27	52	0	CD	_	28	num	_
28	weeks	week	NNS	_	26	pobj	_
29	.	.	.	_	6	punct	_

1	Both	both	DT	p2=CC	4	det	_
2	key	key	JJ	_	4	amod	_
3	secondary	secondary	JJ	_	4	amod	_
4	endpoints	endpoint	NNS	_	6	nsubjpass	6:A1=PPT
5	were	be	VBD	_	6	auxpass	_
6	met	meet	VBN	pb=meet.01	0	root	_
7	in	in	IN	_	6	prep	6:AM-LOC
8	the	the	DT	_	12	det	_
9	INPULSIS	inpulsis	NNP	_	11	hmod	_
10	-	-	HYPH	_	11	hyph	_
11	2	0	CD	p2=NNP	12	nn	_
12	trial	trial	NN	_	7	pobj	_
13	,	,	,	_	12	punct	_
14	namely	namely	RB	_	16	advmod	_
15	significantly	significantly	RB	_	16	advmod	_
16	less	less	JJR	p2=JJS	17	amod	_
17	deterioration	deterioration	NN	_	12	appos	_
18	in	in	IN	_	17	prep	_
19	quality	quality	NN	_	18	pobj	_
20	of	of	IN	_	19	prep	_
21	life	life	NN	_	20	pobj	_
22	and	and	CC	_	17	cc	_
23	a	a	DT	_	25	det	_
24	reduced	reduce	VBN	p2=JJ|pb=reduce.01	25	amod	_
25	risk	risk	NN	_	17	conj	24:A1=PPT
26	of	of	IN	_	25	prep	_
27	a	a	DT	_	30	det	_
28	first	#ord#	JJ	p2=RB	30	amod	_
29	acute	acute	JJ	p2=NN	30	amod	_
30	exacerbation	exacerbation	NN	_	26	pobj	_
31	in	in	IN	_	30	prep	_
32	patients	patient	NNS	_	31	pobj	33:A0
33	taking	take	VBG	pb=take.01	32	partmod	_
34	nintedanib	nintedanib	CD	p2=NN	33	dobj	33:A1=PPT
35	,	,	,	_	30	punct	_
36	compared	compare	VBN	_	16	prep	_
37	to	to	IN	_	36	prep	_
38	placebo	placebo	NN	_	37	pobj	_
39	.	.	.	_	6	punct	_

1	Study	study	NN	p2=VB	2	nn	_
2	investigator	investigator	NN	_	4	nn	_
3	Luca	luca	NNP	_	4	nn	_
4	Richeldi	richeldi	NNP	_	10	nsubj	10:A0
5	of	of	IN	_	4	prep	_
6	the	the	DT	_	7	det	_
7	University	university	NNP	_	5	pobj	_
8	of	of	IN	_	7	prep	_
9	Southampton	southampton	NNP	_	8	pobj	_
10	said	say	VBD	pb=say.01	0	root	_
11	the	the	DT	_	12	det	_
12	latter	latter	JJ	p2=NN	13	nsubj	13:A1=PPT
13	is	be	VBZ	p2=NN|pb=be.01	10	ccomp	10:A1=PPT
14	of	of	IN	_	13	prep	13:A2=PRD
15	particular	particular	JJ	_	17	amod	_
16	clinical	clinical	JJ	_	17	amod	_
17	importance	importance	NN	_	14	pobj	_
18	,	,	,	_	13	punct	_
19	because	because	IN	_	30	mark	_
20	unlike	unlike	IN	p2=JJ	30	prep	30:AM-ADV
21	with	with	IN	_	20	prep	_
22	chronic	chronic	JJ	_	25	amod	_
23	obstructive	obstructive	JJ	p2=NN	25	amod	_
24	pulmonary	pulmonary	JJ	_	25	amod	_
25	disease	disease	NN	_	21	pobj	_
26	,	,	,	_	30	punct	_
27	"	"	''	p2=``	30	punct	_
28	acute	acute	JJ	p2=IN	29	amod	_
29	exacerbations	exacerbation	NNS	_	30	nsubj	30:A1=PPT
30	are	be	VBP	pb=be.01	13	conj	_
31	rapid	rapid	JJ	_	34	amod	_
32	and	and	CC	_	31	cc	_
33	unexplained	unexplained	JJ	_	31	conj	_
34	episodes	episode	NNS	_	30	attr	43:A0=PAG;30:A2=PRD
35	of	of	IN	_	34	prep	_
36	deterioration	deterioration	NN	_	35	pobj	_
37	in	in	IN	p2=FW	36	prep	_
38	IPF	ipf	NNP	_	37	pobj	_
39	[	[	-LRB-	_	34	punct	_
40	which	which	WDT	_	43	nsubj	43:R-A0
41	]	]	-RRB-	_	43	punct	_
42	can	can	MD	_	43	aux	43:AM-MOD
43	lead	lead	VB	pb=lead.03	34	rcmod	_
44	to	to	IN	_	43	prep	43:A2=PRD
45	death	death	NN	_	44	pobj	_
46	in	in	IN	p2=RB	45	prep	_
47	approximately	approximately	RB	_	48	advmod	_
48	half	half	NN	p2=RB	46	pobj	_
49	of	of	IN	_	48	prep	_
50	the	the	DT	_	51	det	_
51	patients	patient	NNS	_	49	pobj	_
52	.	.	.	_	10	punct	_
53	"	"	''	_	10	punct	_

1	In	in	IN	_	9	prep	9:AM-TMP
2	INPULSIS	inpulsis	NNP	p2=NN	4	hmod	_
3	-	-	HYPH	_	4	hyph	_
4	1	0	CD	p2=NNP	1	pobj	_
5	,	,	,	_	9	punct	_
6	however	however	RB	_	9	advmod	9:AM-DIS
7	,	,	,	_	9	punct	_
8	there	there	EX	_	9	expl	_
9	was	be	VBD	pb=be.02	0	root	_
10	no	no	DT	_	13	det	_
11	statistically	statistically	RB	_	12	advmod	_
12	significant	significant	JJ	_	13	amod	_
13	difference	difference	NN	_	9	attr	9:A1=PPT
14	between	between	IN	_	13	prep	_
15	the	the	DT	_	19	det	_
16	nintedanib	nintedanib	NN	p2=CD	19	nn	_
17	and	and	CC	_	16	cc	_
18	placebo	placebo	NN	_	16	conj	_
19	groups	group	NNS	_	14	pobj	_
20	in	in	IN	_	13	prep	_
21	the	the	DT	_	24	det	_
22	key	key	JJ	p2=NN	24	amod	_
23	secondary	secondary	JJ	_	24	amod	_
24	endpoints	endpoint	NNS	_	20	pobj	_
25	.	.	.	_	9	punct	_

1	Prof	prof	NNP	p2=JJ	2	nn	_
2	Richeldi	richeldi	NNP	_	3	nsubj	3:A0=PAG
3	told	tell	VBD	pb=tell.01	0	root	_
4	PharmaTimes	pharmatimes	NNP	p2=NNS	3	dobj	3:A2=GOL
5	here	here	RB	_	3	advmod	3:AM-LOC
6	in	in	IN	_	5	prep	_
7	San	san	NNP	_	8	nn	_
8	Diego	diego	NNP	_	6	pobj	_
9	that	that	IN	_	11	complm	_
10	he	he	PRP	_	11	nsubj	11:A1=PPT
11	is	be	VBZ	pb=be.01	3	ccomp	3:A1=PPT
12	very	very	RB	_	13	advmod	_
13	impressed	impressed	JJ	p2=VBN	11	acomp	11:A2=PRD
14	by	by	IN	_	13	prep	_
15	the	the	DT	_	16	det	_
16	data	datum	NNS	p2=NN	14	pobj	_
17	"	"	''	p2=``	13	punct	_
18	as	as	IN	p2=RB	23	mark	_
19	most	most	JJS	_	20	amod	_
20	trials	trial	NNS	_	18	pobj	_
21	before	before	IN	_	23	mark	_
22	this	this	DT	_	23	nsubj	26:A0=CAU;23:A1=PPT
23	were	be	VBD	pb=be.01	13	advcl	_
24	negative	negative	JJ	_	23	acomp	23:A2=PRD
25	or	or	CC	_	23	cc	_
26	showed	show	VBD	pb=show.01	23	conj	_
27	increased	increase	VBN	p2=JJ|pb=increase.01	28	amod	_
28	mortality	mortality	NN	_	26	dobj	26:A1=PPT;27:A1=PPT
29	in	in	IN	_	28	prep	_
30	the	the	DT	_	32	det	_
31	treatment	treatment	NN	_	32	nn	_
32	arm	arm	NN	_	29	pobj	_
33	"	"	''	_	32	punct	_
34	.	.	.	_	3	punct	_

1	He	he	PRP	_	2	nsubj	2:A0=PAG;25:A0=PAG
2	added	add	VBD	pb=add.01	0	root	_
3	that	that	IN	_	11	complm	_
4	"	"	``	_	11	punct	_
5	for	for	IN	_	11	prep	11:AM-TMP
6	the	the	DT	_	9	det	_
7	very	very	RB	_	8	advmod	_
8	first	#ord#	JJ	_	9	amod	_
9	time	time	NN	_	5	pobj	_
10	we	we	PRP	_	11	nsubj	11:A0
11	see	see	VBP	pb=see.01	2	ccomp	2:A1=PPT
12	two	#crd#	CD	_	14	num	_
13	massive	massive	JJ	_	14	amod	_
14	trials	trial	NNS	_	15	nsubj	15:A0=PAG
15	providing	provide	VBG	pb=provide.01	11	ccomp	11:A1
16	exactly	exactly	RB	_	19	advmod	_
17	the	the	DT	_	19	det	_
18	same	same	JJ	_	19	amod	_
19	results	result	NNS	_	15	dobj	15:A1=PPT
20	over	over	IN	_	19	prep	_
21	one	#crd#	CD	_	22	num	_
22	year	year	NN	_	20	pobj	_
23	"	"	''	_	2	punct	_
24	,	,	,	_	2	punct	_
25	highlighting	highlight	VBG	pb=highlight.01	2	advcl	_
26	the	the	DT	_	28	det	_
27	global	global	JJ	_	28	amod	_
28	reach	reach	NN	_	25	dobj	25:A1=PPT
29	of	of	IN	_	28	prep	_
30	the	the	DT	_	31	det	_
31	studies	study	NNS	_	29	pobj	_
32	(	(	-LRB-	_	31	punct	_
33	including	include	VBG	_	31	prep	_
34	India	india	NNP	_	33	pobj	_
35	,	,	,	_	34	punct	_
36	China	china	NNP	_	34	conj	_
37	,	,	,	_	36	punct	_
38	Europe	europe	NNP	_	36	conj	_
39	and	and	CC	_	38	cc	_
40	North	north	NNP	_	43	nn	_
41	and	and	CC	_	40	cc	_
42	South	south	NNP	_	43	nn	_
43	America	america	NNP	_	38	conj	_
44	)	)	-RRB-	_	31	punct	_
45	and	and	CC	_	28	cc	_
46	the	the	DT	_	47	det	_
47	fact	fact	NN	_	28	conj	_
48	that	that	IN	_	51	complm	_
49	the	the	DT	_	50	det	_
50	results	result	NNS	_	51	nsubj	51:A1=PPT
51	were	be	VBD	pb=be.01	47	ccomp	_
52	"	"	``	_	54	punct	_
53	remarkably	remarkably	RB	_	54	advmod	_
54	similar	similar	JJ	p2=RB	51	acomp	51:A2=PRD
55	"	"	''	_	54	punct	_
56	to	to	IN	_	54	prep	_
57	those	those	DT	_	56	pobj	58:A1
58	seen	see	VBN	pb=see.01	57	partmod	_
59	in	in	IN	_	58	prep	58:AM-LOC
60	Phase	phase	NNP	p2=NN	59	pobj	_
61	II	ii	NNP	_	60	num	_
62	.	.	.	_	2	punct	_

1	Charles	charles	NNP	_	3	nn	_
2	de	de	NNP	p2=FW	3	nn	_
3	Wet	wet	NNP	_	11	nsubj	11:A0
4	,	,	,	_	3	punct	_
5	Boehringer	boehringer	NNP	_	9	poss	_
6	's	's	POS	_	5	possessive	_
7	UK	uk	NNP	_	9	nn	_
8	medical	medical	JJ	_	9	amod	_
9	director	director	NN	_	3	appos	_
10	,	,	,	_	3	punct	_
11	said	say	VBD	pb=say.01	0	root	_
12	"	"	``	_	11	punct	_
13	we	we	PRP	_	14	nsubj	14:A1=PPT
14	are	be	VBP	pb=be.01	11	ccomp	11:A1=PPT
15	delighted	delighted	JJ	_	14	acomp	14:A2=PRD
16	that	that	IN	_	22	complm	_
17	these	these	DT	_	21	det	_
18	latest	late	JJS	_	21	amod	_
19	Phase	phase	NNP	p2=NN	20	nn	_
20	III	iii	NNP	p2=CD	21	nn	_
21	results	result	NNS	_	22	nsubj	22:A0=CAU
22	show	show	VBP	pb=show.01	15	ccomp	_
23	benefits	benefit	NNS	_	22	dobj	22:A1=PPT
24	for	for	IN	_	23	prep	_
25	patients	patient	NNS	_	24	pobj	_
26	with	with	IN	_	25	prep	_
27	this	this	DT	_	29	det	_
28	devastating	devastating	JJ	_	29	amod	_
29	disease	disease	NN	_	26	pobj	_
30	"	"	''	_	29	punct	_
31	,	,	,	_	22	punct	_
32	adding	add	VBG	pb=add.01	22	advcl	_
33	that	that	IN	_	36	complm	_
34	"	"	``	_	36	punct	_
35	we	we	PRP	_	36	nsubj	36:A0=PAG
36	have	have	VBP	pb=have.03	32	ccomp	32:A1=PPT
37	a	a	DT	_	39	det	_
38	long	long	JJ	_	39	amod	_
39	heritage	heritage	NN	_	36	dobj	36:A1=PPT
40	in	in	IN	_	36	prep	36:AM-LOC
41	the	the	DT	_	43	det	_
42	respiratory	respiratory	JJ	_	43	amod	_
43	arena	arena	NN	_	40	pobj	_
44	"	"	''	_	36	punct	_
45	.	.	.	_	11	punct	_

1	The	the	DT	_	3	det	_
2	nintedanib	nintedanib	JJ	p2=NN	3	amod	_
3	data	datum	NNS	p2=NN	6	nsubjpass	6:A1=PPT
4	will	will	MD	_	6	aux	6:AM-MOD
5	be	be	VB	_	6	auxpass	_
6	presented	present	VBN	pb=present.01	0	root	_
7	during	during	IN	_	6	prep	6:AM-TMP
8	the	the	DT	_	11	det	_
9	New	new	NNP	_	10	nn	_
10	England	england	NNP	_	11	nn	_
11	Journal	journal	NNP	_	7	pobj	_
12	of	of	IN	_	11	prep	_
13	Medicine	medicine	NNP	_	12	pobj	_
14	and	and	CC	_	11	cc	_
15	the	the	DT	_	16	det	_
16	Journal	journal	NNP	_	11	conj	_
17	of	of	IN	_	16	prep	_
18	the	the	DT	_	21	det	_
19	American	american	NNP	_	21	nn	_
20	Medical	medical	NNP	_	21	nn	_
21	Association	association	NNP	_	17	pobj	_
22	here	here	RB	_	6	advmod	_
23	at	at	IN	_	22	prep	_
24	the	the	DT	_	25	det	_
25	ATS	ats	NNP	p2=NNPS	23	pobj	_
26	(	(	-LRB-	_	25	punct	_
27	10	0	CD	_	28	num	_
28	pm	pm	NN	_	30	nn	_
29	UK	uk	NNP	p2=NN	30	nn	_
30	time	time	NN	_	25	appos	_
31	)	)	-RRB-	_	25	punct	_
32	.	.	.	_	6	punct	_

1	The	the	DT	_	3	det	_
2	meeting	meeting	NN	_	3	nn	_
3	room	room	NN	_	6	nsubjpass	6:A1=GOL
4	will	will	MD	_	6	aux	6:AM-MOD
5	be	be	VB	_	6	auxpass	_
6	packed	pack	VBN	p2=JJ|pb=pack.01	0	root	_
7	for	for	IN	_	6	prep	6:A2=PPT
8	the	the	DT	_	9	det	_
9	session	session	NN	_	7	pobj	_
10	as	as	IN	_	9	prep	_
11	data	datum	NNS	p2=NN	10	pobj	_
12	from	from	IN	_	11	prep	_
13	InterMune	intermune	NNP	_	16	poss	_
14	's	's	POS	_	13	possessive	_
15	ASCEND	ascend	NNP	p2=NN	16	nn	_
16	study	study	NN	_	12	pobj	_
17	on	on	IN	_	16	prep	_
18	its	its	PRP$	_	20	poss	_
19	IPF	ipf	NNP	p2=NN	21	nn	_
20	drug	drug	NN	_	21	nn	_
21	Esbriet	esbriet	NNP	p2=NN	28	nsubjpass	28:A1=PPT
22	(	(	-LRB-	_	23	punct	_
23	pirfenidone	pirfenidone	NN	_	21	appos	_
24	)	)	-RRB-	_	23	punct	_
25	will	will	MD	_	28	aux	28:AM-MOD
26	also	also	RB	_	28	advmod	28:AM-ADV
27	be	be	VB	_	28	auxpass	_
28	presented	present	VBN	pb=present.01	6	conj	_
29	and	and	CC	_	28	cc	_
30	there	there	EX	_	32	expl	_
31	will	will	MD	_	32	aux	32:AM-MOD
32	be	be	VB	pb=be.02	28	conj	_
33	a	a	DT	_	34	det	_
34	discussion	discussion	NN	_	32	attr	32:A1=PPT;47:A1=PPT
35	on	on	IN	_	34	prep	_
36	the	the	DT	_	37	det	_
37	merits	merit	NNS	_	35	pobj	_
38	of	of	IN	_	37	prep	_
39	the	the	DT	_	41	det	_
40	two	#crd#	CD	_	41	num	_
41	treatments	treatment	NNS	_	38	pobj	_
42	(	(	-LRB-	_	41	punct	_
43	analysis	analysis	NN	_	41	appos	_
44	on	on	IN	_	43	prep	_
45	PharmaTimes	pharmatimes	NNS	p2=NNP	44	pobj	_
46	to	to	TO	_	47	aux	_
47	follow	follow	VB	pb=follow.02	34	infmod	_
48	)	)	-RRB-	_	32	punct	_
49	.	.	.	_	6	punct	_

